drugset
drugset / Trial / NCT06841445

Efficacy and Safety of HRS9531 Tablet in Obese Subjects

NCT06841445 ↗

Phase 2 Completed 166 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.

Timeline

Start
2025-04-07
Primary completion
2026-01-08
Completion
2026-01-08

Outcome

Met primary endpoint

release “Hengrui’s Phase 2 clinical trial of once-daily ribupatide oral (also known as HRS9531 pill and KAI-9531-T) in China met its primary endpoint” kailera.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown — —

Indications

No indication recorded.